Using the SurvExpress web tool [51], we found that RHOB expression had conflicted predictive value for cancer progression (Figure 11A,B), whereas high VIM and ITGB2 expression were positively correlated with low metastasis-free/recurrence-free survival in lung adenocarcinoma (Figure 11C,E) and breast cancer (Figure 11D,F) cohorts. The gene discussed is ITGB2; the disease is breast cancer.